Publications
October 14, 2024
Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal…
April 11, 2016
Activity of the novel Fabl inhibitor Debio 1452 against intracellular forms of susceptible and resistant S. aureus: comparison with linezolid,…